References
- Lakey WC, Barnard K, Batch BC, Chiswell K, Tasneem A, Green JB. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia 56, 1226–1235 ((2013)).
- Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374, 1677–1686 ((2009)).
- Chiasson JL, Josse RG, Gomis R, Henfeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359, 2072–2077 (2002).
- The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54, 1150–1156 (2005).
- Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51, 2796–2803 (2002).
- Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized, controlled trial. Lancet 368, 1096–1105 (2006).
- DeFronzo RA, Tripathy D, Schwenke DC et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. NEJM 364, 1104–1115 (2011).
- Crandall JP, Knowler WC, Kahn SE et al. The prevention of type 2 diabetes. Nat. Clin. Pract. Endocrinol. Metab. 4(7), 382–393 (2008).
- Carlsson LMS, Peltonen M, Ahlin S et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. NEJM 367(8), 695–704 (2012).
- Ma J, Yank V, Xiao L et al. Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care. JAMA Intern. Med. 173(2), 113–121 (2013).
- Ali M, Echouffo-Tcheugui J, Williamson D. How effective were lifestyle interventions in real-world settings that were modeled on the diabetes prevention program? Health Aff. 31(1), 67–75 (2012).
- Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49, 289–297 (2006).
- Sjoholm K, Romeo S, Anveden A et al. Evaluation of current eligibility criteria for bariatric surgery. Diabetes Care 36, 1335–1340 (2013).
- Lakubovich N, Gerstein HC. Is regression to normoglycaemia clinically important? Lancet 379, 2216–2218 (2012).
Website
- International Diabetes Federation. IDF Diabetes Atlas, 5th Edition. International Diabetes Federation, Brussels (2012). www.idf.org/diabetesatlas (Accessed 13 June 2013).